What's new — Fibromyalgia¶
Generated 2026-09-03 from the publication dates of every paper cited in this condition's pages.
This page answers a different question from the curation log. The log says when we last edited a page; this says how recent the evidence on those pages is — so you can tell settled ground from a field that is actively moving, and jump straight to what has emerged lately.
How much of this condition's evidence is recent¶
| Published within | Cited papers |
|---|---|
| last week | 0 |
| last month | 0 |
| last 2 months | 0 |
| last 3 months | 6 |
| last 6 months | 10 |
| last year | 20 |
| older than a year | 372 |
Counts are cumulative: a paper from last week also counts inside "last month". Dates are PubMed publication or e-publication dates, so a paper may have appeared online before its journal issue.
Newest evidence first¶
The most recent cited papers, with the pages that use them.
| Published | Paper | Cited on |
|---|---|---|
| 2026-07-02 | Trends in incidence, patient characteristics, healthcare use, and medication in fibromyalgia: A large Israeli cohort study — Semin Arthritis Rheum ([PMID 42551405](https://pubmed.ncbi.nlm.nih.gov/42551405/){target="_blank" rel="noopener"}) | epidemiology |
| 2026-07-02 | The genetic architecture of fibromyalgia across 2.5 million individuals — Nat Med ([PMID 42521817](https://pubmed.ncbi.nlm.nih.gov/42521817/){target="_blank" rel="noopener"}) | clinical-trials-landscape, comorbidities-and-overlap, genetics-and-risk-factors, omics-and-emerging-science |
| 2026-07-02 | Sublingual Cyclobenzaprine for Fibromyalgia: Pharmacokinetic Rationale, Clinical Evidence, and Place in Therapy — Curr Pain Headache Rep ([PMID 42479282](https://pubmed.ncbi.nlm.nih.gov/42479282/){target="_blank" rel="noopener"}) | clinical-trials-landscape, guidelines, pharmacologic-therapy |
| 2026-07-01 | Absence of a Consistent Gut or Oral Microbial Signature in Fibromyalgia Under Strictly Controlled Clinical Conditions: A Multi-Compartment 16S rRNA Analysis — Pain Physician ([PMID 42550534](https://pubmed.ncbi.nlm.nih.gov/42550534/){target="_blank" rel="noopener"}) | biomarkers, omics-and-emerging-science |
| 2026-07-01 | fAI-BRO: a multimodal AI decision-support system to address diagnostic delay in fibromyalgia syndrome — RMD Open ([PMID 42442924](https://pubmed.ncbi.nlm.nih.gov/42442924/){target="_blank" rel="noopener"}) | biomarkers, omics-and-emerging-science, patient-experience-and-advocacy |
| 2026-06-04 | Fibromyalgia in systemic autoimmune rheumatic diseases: a mixed-methods study of patient and clinician perspectives — Rheumatol Int ([PMID 42236570](https://pubmed.ncbi.nlm.nih.gov/42236570/){target="_blank" rel="noopener"}) | patient-experience-and-advocacy |
| 2026-05-02 | A systematic scoping review and conceptual analysis of new-onset fibromyalgia manifestations after non-hospitalized COVID-19: empirics, definitions, methodologies, pathophysiology, mapping of literature, and knowledge gaps — J Transl Med ([PMID 42174645](https://pubmed.ncbi.nlm.nih.gov/42174645/){target="_blank" rel="noopener"}) | comorbidities-and-overlap, genetics-and-risk-factors |
| 2026-04-09 | Mechanical sensitization of sensory afferents after passive transfer of fibromyalgia IgG — J Physiol ([PMID 41955337](https://pubmed.ncbi.nlm.nih.gov/41955337/){target="_blank" rel="noopener"}) | autoimmunity-and-inflammation |
| 2026-04-03 | Low-Dose Naltrexone: What is the Evidence? A Narrative Review — Adv Ther ([PMID 42060160](https://pubmed.ncbi.nlm.nih.gov/42060160/){target="_blank" rel="noopener"}) | pharmacologic-therapy |
| 2026-04-01 | Steady-State Pharmacokinetic Properties of TNX-102 SL, a Sublingual Tablet Formulation of Cyclobenzaprine Hydrochloride (HCl), With Daily Dosing in Healthy Volunteers: A Randomized, Open-Label Trial — Clin Pharmacol Drug Dev ([PMID 41948806](https://pubmed.ncbi.nlm.nih.gov/41948806/){target="_blank" rel="noopener"}) | guidelines, pharmacologic-therapy |
| 2026-03-01 | Single-Dose Pharmacokinetic Assessment of TNX-102 SL (Cyclobenzaprine HCl Sublingual Tablets): Results From Randomized, Open-Label Studies in Healthy Volunteers — Clin Pharmacol Drug Dev ([PMID 41749492](https://pubmed.ncbi.nlm.nih.gov/41749492/){target="_blank" rel="noopener"}) | pharmacologic-therapy |
| 2026-02-02 | Microbially produced bile acids are associated with increased IgG autoantibodies and poorer mental wellbeing in fibromyalgia — Sci Rep ([PMID 41735414](https://pubmed.ncbi.nlm.nih.gov/41735414/){target="_blank" rel="noopener"}) | autoimmunity-and-inflammation |
| 2026-01-02 | Shared latent genetic liability across fibromyalgia and psychiatric traits: Novel insights from genomic structural equation modeling — PLoS Genet ([PMID 41576141](https://pubmed.ncbi.nlm.nih.gov/41576141/){target="_blank" rel="noopener"}) | comorbidities-and-overlap, genetics-and-risk-factors |
| 2026-01-01 | Pain relief by targeting nonrestorative sleep in fibromyalgia: a phase 3 randomized trial of bedtime sublingual cyclobenzaprine — Pain Med ([PMID 40627411](https://pubmed.ncbi.nlm.nih.gov/40627411/){target="_blank" rel="noopener"}) | clinical-trials-landscape, outcomes-and-measurement, pharmacologic-therapy |
| 2025-12-01 | Exploring gut microbiota alterations and their associations with clinical symptoms in fibromyalgia — Sci Rep ([PMID 41390899](https://pubmed.ncbi.nlm.nih.gov/41390899/){target="_blank" rel="noopener"}) | omics-and-emerging-science |
| 2025-11-04 | Aβ low threshold mechanoreceptors contribute to sensory abnormalities in fibromyalgia — Brain ([PMID 40898777](https://pubmed.ncbi.nlm.nih.gov/40898777/){target="_blank" rel="noopener"}) | autoimmunity-and-inflammation, biomarkers, omics-and-emerging-science, pathophysiology-peripheral |
| 2025-11-02 | Short-term efficacy and safety of sublingual cyclobenzaprine for fibromyalgia: A systematic review and meta-analysis — Clin Rheumatol ([PMID 41318845](https://pubmed.ncbi.nlm.nih.gov/41318845/){target="_blank" rel="noopener"}) | pharmacologic-therapy |
| 2025-11-01 | Evaluating the Accuracy of the Frysian Questionnaire for Differentiation of Musculoskeletal Complaints for Triage of Musculoskeletal Diseases: Algorithm Development and Validation Study — JMIR Med Inform ([PMID 41248315](https://pubmed.ncbi.nlm.nih.gov/41248315/){target="_blank" rel="noopener"}) | biomarkers, omics-and-emerging-science |
| 2025-10-05 | Efficacy and safety of TNX-102 SL in patients with fibromyalgia: a systematic review and meta-analysis — Pain Manag ([PMID 41047726](https://pubmed.ncbi.nlm.nih.gov/41047726/){target="_blank" rel="noopener"}) | pharmacologic-therapy |
| 2025-10-02 | Fibromyalgia diagnosis from a multi-omics approach: a gut feeling — Front Microbiol ([PMID 41113645](https://pubmed.ncbi.nlm.nih.gov/41113645/){target="_blank" rel="noopener"}) | biomarkers, omics-and-emerging-science |
Trials — what has moved¶
74 registered trials are cited by this condition's pages. Registry records were re-checked live when this page was generated, so status, enrolment and results-posting below reflect ClinicalTrials.gov as of that date.
| Registry activity | Trials |
|---|---|
| trial records updated in the last week | 2 |
| trial records updated in the last month | 7 |
| trial records updated in the last 2 months | 10 |
| trial records updated in the last 3 months | 12 |
| trial records updated in the last 6 months | 21 |
| trial records updated in the last year | 31 |
Recently updated registrations¶
Posted efficacy and safety results¶
Trials whose sponsors have posted results to the registry. Adverse-event figures are participant counts summed across all arms as reported — read them against enrolment, and follow the registry link for the arm-by-arm breakdown that determines whether a signal is real.
| Results posted | Trial | Phase | N | Primary outcome | Serious AE | Other AE | Deaths |
|---|---|---|---|---|---|---|---|
| 2026-02-02 | Anti-CGRP for Inflammation and Pain Modulation in Small Fiber Neuropat | PHASE4 | 26 | Change in Pain Score | 0 | 13 | 0 |
| 2025-04-16 | Open-label Study to Assess the Safety and Efficacy of Psilocybin With | PHASE2 | 17 | Heart Rate Beats Per Minute (BPM) - First Dose (15 mg) | 0 | 4 | 0 |
| 2025-02-25 | Repeat of: A Study to Evaluate Efficacy and Safety of Sublingual TNX-1 | PHASE3 | 51 | Weekly Mean Pain Score | 0 | 0 | 0 |
| 2025-02-07 | A Study to Evaluate eFFIcacy and Safety of Sublingual TNX-102 SL Table | PHASE3 | 519 | Proportion of Patients With ≥30% Pain Improvement | 7 | 149 | 0 |
| 2024-12-20 | A Phase 3 Study to Evaluate the Efficacy and Safety of TNX-102 SL Take | PHASE3 | 457 | Change From Baseline to the Week 14 Endpoint in the Diary NRS Weekly A | 5 | 82 | 0 |
| 2024-12-11 | A 3-Month Open-Label Safety and Efficacy Study of TNX-102 SL Tablets i | PHASE3 | 375 | Newly Emergent Adverse Events | 2 | 155 | 0 |
| 2023-09-13 | IVIg for Small Fiber Neuropathy With Autoantibodies TS-HDS and FGFR3 | PHASE2 | 20 | The Change in Nerve Fiber Density Between Visits 1 and 8. | 0 | 17 | 0 |
| 2022-12-02 | A Phase 3 Study To Evaluate The Efficacy And Safety Of TNX-102 SL In P | PHASE3 | 514 | Change From Baseline to Week 14 in the Numerical Rating Scale (NRS) We | 6 | 85 | 0 |
| 2022-08-08 | A Study To Evaluate The Efficacy And Safety Of TNX-102 SL In Patients | PHASE3 | 503 | Change From Baseline to Week 14 in the Numerical Rating Scale (NRS) We | 7 | 73 | 0 |
| 2021-10-06 | Cyclobenzaprine Extended Release (ER) for Fibromyalgia | PHASE4 | 37 | Visual Analogue Pain Scale at 8 Weeks Post Treatment | 0 | 3 | 0 |
| 2017-07-07 | 12-Month Open-Label Long-term Safety Study of TNX-102 SL Tablets in Fi | PHASE3 | 158 | Newly-emergent Adverse Events (NEAEs) During Treatment With TNX-102 SL | 8 | 82 | 0 |
| 2017-04-11 | Low Dose Naltrexone (LDN) Immune Monitoring | NA | 9 | Change in IL-1α From Baseline. | 0 | 0 | 0 |
| 2017-04-11 | rTMS for the Treatment of Chronic Pain in GW1 Veterans | PHASE3 | 17 | Change in the Brief Pain Inventory (Short Form) Score | 1 | 2 | 0 |
| 2016-12-23 | BEdtime Sublingual TNX-102 SL as Fibromyalgia Intervention Therapy (BE | PHASE2, PHASE3 | 205 | Mean Change From Baseline in Weekly Average of Daily Pain Scores at We | 1 | 79 | 0 |
| 2015-10-21 | Effects of Low Dose Naltrexone in Fibromyalgia | NA | 53 | Percent Change in Pain Scores Between Baseline to End of Placebo Treat | 0 | 27 | 0 |
34 of these trials are still recruiting or active — see the condition's clinical trials page for the full landscape.
Which pages rest on the newest evidence¶
🔥 marks a page citing three or more papers from the last year — the pages worth re-reading if you have been away.
| Page | Newest citation | In last year | Total citations |
|---|---|---|---|
| clinical-trials-landscape | 2026-07-02 | 3 | 24 |
| comorbidities-and-overlap | 2026-07-02 | 3 | 26 |
| epidemiology | 2026-07-02 | 1 | 27 |
| genetics-and-risk-factors | 2026-07-02 | 3 | 34 |
| guidelines | 2026-07-02 | 2 | 27 |
| omics-and-emerging-science | 2026-07-02 | 7 | 33 |
| pharmacologic-therapy | 2026-07-02 | 7 | 49 |
| biomarkers | 2026-07-01 | 5 | 29 |
| patient-experience-and-advocacy | 2026-07-01 | 2 | 44 |
| autoimmunity-and-inflammation | 2026-04-09 | 3 | 22 |
| outcomes-and-measurement | 2026-01-01 | 1 | 22 |
| pathophysiology-peripheral | 2025-11-04 | 1 | 23 |
| non-pharmacologic-therapy | 2025-06-04 | 0 | 29 |
| pathophysiology-central | 2024-11-02 | 0 | 34 |
| red-flags-and-safety-concerns | 2023-10-01 | 0 | 44 |
| overview | 2023-07-01 | 0 | 27 |
| diagnostic-criteria | 2022-11-01 | 0 | 24 |
| history-and-nosology | 2021-11-01 | 0 | 36 |
| sleep-fatigue-cognition | 2019-02-02 | 0 | 18 |
Recency is not quality: an old paper may be the definitive one, and a new paper may not replicate. Use this to find movement, not to rank evidence. See open questions for what remains unresolved, and the curation log for when these pages were last revised.